Halozyme Overview

  • Founded
  • 1998

Founded
  • Status
  • Public

  • Employees
  • 145

Employees
  • Stock Symbol
  • HALO

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $51.12

  • (As of Monday Closing)

Halozyme General Information

Description

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Contact Information

Formerly Known As
Global Yacht Services
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Stock Exchange
NAS
Primary Office
  • 11388 Sorrento Valley Road
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Halozyme Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$51.12 $50.71 $32.00 - $59.46 $6.91B 135M 1.31M $1.53

Halozyme Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 6,544,319 5,720,831 5,820,593 2,423,994
Revenue 580,623 443,310 267,594 195,992
EBITDA 290,669 259,044 152,964 (56,556)
Net Income 211,197 402,710 129,085 (72,240)
Total Assets 1,864,543 1,104,429 579,924 565,874
Total Debt 1,504,471 876,674 397,228 402,587
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Halozyme Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Halozyme‘s full profile, request access.

Request a free trial

Halozyme Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies.
Biotechnology
San Diego, CA
145 As of 2021
00000
00000000 00000

00 000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupid
0000000000000
Durham, NC
000 As of 0000
00000
00000000 00000

00000

mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000 000000000
San Diego, CA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Halozyme Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
G1 Therapeutics Formerly VC-backed Durham, NC 000 00000 00000000 00000
00000 000000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
0000000-00000 0000 Corporation New York, NY 00000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Hampton, NJ 000 00000 00000000 00000
00000 Corporation Basel, Switzerland 000000 00.000 00000000000 00.000
You’re viewing 5 of 11 competitors. Get the full list »

Halozyme Patents

Halozyme Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220233689-A1 Methods of treating tumors Pending 28-Dec-2020 000000000000
US-20220233693-A1 Antibody compositions and methods of use thereof Pending 28-Dec-2020 000000000000
US-20190351031-A1 Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 Inactive 16-May-2018 000000000
AU-2018236742-A1 Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same Active 14-Oct-2014 00000000
AU-2018236742-B2 Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same Active 14-Oct-2014 C12N9/78
To view Halozyme’s complete patent history, request access »

Halozyme Executive Team (38)

Name Title Board Seat Contact Info
Helen Torley President, Chief Executive Officer & Board Member
Nicole LaBrosse Chief Financial Officer, Finance & Senior Vice President
Elaine Sun Chief Financial Officer & Senior Vice President
Michael LaBarre Ph.D Chief Technology Officer, Technology & Senior Vice President
Tood Butler Chief Of Staff to the CEO; Vice President & Head of Project Management
You’re viewing 5 of 38 executive team members. Get the full list »

Halozyme Board Members (14)

Name Representing Role Since
Bernadette Connaughton Halozyme Board Member 000 0000
Connie Matsui Self Chairman & Board Member 000 0000
Helen Torley Halozyme President, Chief Executive Officer & Board Member 000 0000
James Daly Self Board Member 000 0000
Jean-Pierre Bizzari MD Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Halozyme Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Halozyme Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Halozyme‘s full profile, request access.

Request a free trial

Halozyme Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 24-May-2022 0000000000 00.000 Pharmaceuticals 00000 000
Global Yacht Services 11-Mar-2004 Merger/Acquisition Other Services (B2C Non-Financial)
To view Halozyme’s complete acquisitions history, request access »

Halozyme Subsidiaries (1)

Company Name Industry Location Founded
0000000 000000 Pharmaceuticals Ewing, NJ 0000
To view Halozyme’s complete subsidiaries history, request access »

Halozyme ESG

Risk Overview

Risk Rating

Updated May, 18, 2022

23.76 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 462

Rank

00.00

Percentile

To view Halozyme’s complete esg history, request access »